title: Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patients.
authors.affiliation: Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Spratt
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Zelefsky
mesh_terms: D001918:Brachytherapy / Q000379:methods*; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000532:radiotherapy*; D016896:Treatment Outcome